Here’s a real breakdown of what it actually costs to maintain a lifted Duramax over the course of a year. From routine ...

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than two months. Remarkably, it achieved rallies exceeding 50% on two occasions, ...

The obesity and diabetes drug boom is no longer a one-cycle story. Demand for GLP-1 treatments continues to exceed supply, with physicians expanding use beyond diabetes into weight management and ...

In the latest weekly data update, Eli Lilly's quality score advanced from 89.66 to 90.04. This uptick pushes the stock into the “elite” tier of the market, ranking it higher than 90% of its peers.

Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the company's lead in this niche of the industry. Even after their strong run, Lilly's ...

These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo ...

Orforglipron maintains weight loss after switching from injectable GLP-1 drugs Lilly and Novo Nordisk await U.S. regulatory approvals for weight-loss pills FDA may expedite review of Lilly's ...

Shares of Eli Lilly (LLY) are down about 1% in early trading on Dec. 23 on news that archrival Novo Nordisk’s (NVO) new weight-loss pill has received regulatory approval in the U.S. LLY stock is ...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products ...